Pharmacy Times July 6, 2024
Real-world data and artificial intelligence (AI) are poised to revolutionize drug development by optimizing clinical trials and regulatory approvals, if data quality and patient privacy challenges are addressed.
Earlier this month, Dandelion Health announced the launch of the first artificial intelligence (AI) database specifically aimed at bolstering research for GLP-1 drugs, giving trial sponsors unprecedented insights into which indications to investigate next.1 The announcement from Dandelion is the latest example of a growing desire in health care analytics to use AI and machine learning (ML)–driven analysis of real-world data (RWD) to find new indications for approved drugs.
Beyond research and development for new indications and molecule structures, AI technology could be revolutionary for clinical trials, helping vastly reduce the cost...
Today's Sponsors
Today's Sponsor